TY - JOUR
T1 - Gastrointestinal symptoms as an extended clinical feature of Pierson syndrome
T2 - A case report and review of the literature
AU - Nishiyama, Kei
AU - Kurokawa, Mari
AU - Torio, Michiko
AU - Sakai, Yasunari
AU - Arima, Mitsuru
AU - Tsukamoto, Shoko
AU - Obata, Satoshi
AU - Minamikawa, Shogo
AU - Nozu, Kandai
AU - Kaku, Noriyuki
AU - Maehara, Yoshihiko
AU - Sonoda, Koh Hei
AU - Taguchi, Tomoaki
AU - Ohga, Shouichi
N1 - Funding Information:
This work was supported by the JSPS KAKENHI grant numbers JP17K16301, JP17K17334 and JP19K08281 in the design of the study, collection, interpretation and analysis of data; a Health and Labour Sciences Research Grant on Evidence-based Early Diagnosis and Treatment Strategies for Neu-roimmunological Diseases from the Ministry of Health, Labour and Welfare of Japan for writing the manuscript and the design of this study; Life Science Foundation of Japan, Takeda Science Foundation, The Mother and Child Health Foundation, The Japan Epilepsy Research Foundation, and Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics in writing the manuscript.
Publisher Copyright:
© 2020 The Author(s).
PY - 2020/4/15
Y1 - 2020/4/15
N2 - Background: Pierson syndrome (PS) is a rare autosomal recessive disorder, characterized by congenital nephrotic syndrome and microcoria. Advances in renal replacement therapies have extended the lifespan of patients, whereas the full clinical spectrum of PS in infancy and beyond remains elusive. Case presentation: We present the case of a 12-month-old boy with PS, manifesting as the bilateral microcoria and congenital nephrotic syndrome. He was born without asphyxia, and was neurologically intact from birth through the neonatal period. Generalized muscle weakness and hypotonia were recognized from 3 months of age. The infant showed recurrent vomiting at age 5 months of age, and was diagnosed with gastroesophageal reflux and intestinal malrotation. Despite the successful surgical treatment, vomiting persisted and led to severely impaired growth. Tulobuterol treatment was effective in reducing the frequency of vomiting. Targeted sequencing confirmed that he had a compound heterozygous mutation in LAMB2 (NM_002292.3: P.Arg550X and p.Glu1507X). A search of the relevant literature identified 19 patients with severe neuro-muscular phenotypes. Among these, only 8 survived the first 12 months of life, and one had feeding difficulty with similar gastrointestinal problems. Conclusions: This report demonstrated that severe neurological deficits and gastrointestinal dysfunction may emerge in PS patients after the first few months of life.
AB - Background: Pierson syndrome (PS) is a rare autosomal recessive disorder, characterized by congenital nephrotic syndrome and microcoria. Advances in renal replacement therapies have extended the lifespan of patients, whereas the full clinical spectrum of PS in infancy and beyond remains elusive. Case presentation: We present the case of a 12-month-old boy with PS, manifesting as the bilateral microcoria and congenital nephrotic syndrome. He was born without asphyxia, and was neurologically intact from birth through the neonatal period. Generalized muscle weakness and hypotonia were recognized from 3 months of age. The infant showed recurrent vomiting at age 5 months of age, and was diagnosed with gastroesophageal reflux and intestinal malrotation. Despite the successful surgical treatment, vomiting persisted and led to severely impaired growth. Tulobuterol treatment was effective in reducing the frequency of vomiting. Targeted sequencing confirmed that he had a compound heterozygous mutation in LAMB2 (NM_002292.3: P.Arg550X and p.Glu1507X). A search of the relevant literature identified 19 patients with severe neuro-muscular phenotypes. Among these, only 8 survived the first 12 months of life, and one had feeding difficulty with similar gastrointestinal problems. Conclusions: This report demonstrated that severe neurological deficits and gastrointestinal dysfunction may emerge in PS patients after the first few months of life.
UR - http://www.scopus.com/inward/record.url?scp=85083478271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083478271&partnerID=8YFLogxK
U2 - 10.1186/s12881-020-01019-9
DO - 10.1186/s12881-020-01019-9
M3 - Review article
C2 - 32295525
AN - SCOPUS:85083478271
SN - 1471-2350
VL - 21
JO - BMC Medical Genetics
JF - BMC Medical Genetics
IS - 1
M1 - 80
ER -